dc.contributor.author | Abu Al Magd, Megahed | |
dc.contributor.author | Karadeniz, Sehnaz | |
dc.contributor.author | Meriden, Terry | |
dc.contributor.author | Misha'l, Aly A. | |
dc.contributor.author | Pozzilli, Paolo | |
dc.contributor.author | Shera, Samad | |
dc.contributor.author | Thomas, Abraham | |
dc.contributor.author | Bahijri, Suhad | |
dc.contributor.author | Tuomilehto, Jaakko | |
dc.contributor.author | Yilmaz, Temel | |
dc.contributor.author | Umpierrez, Guillermo E. | |
dc.contributor.author | Ibrahim, Mahmoud | |
dc.contributor.author | Annabi, Firas A. | |
dc.contributor.author | Assaad-Khalil, Samir | |
dc.contributor.author | Ba-Essa, Ebtesam M. | |
dc.contributor.author | Fahdil, Ibtihal | |
dc.date.accessioned | 2021-03-04T10:57:23Z | |
dc.date.available | 2021-03-04T10:57:23Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | Ibrahim M., Abu Al Magd M., Annabi F. A. , Assaad-Khalil S., Ba-Essa E. M. , Fahdil I., Karadeniz S., Meriden T., Misha'l A. A. , Pozzilli P., et al., "Recommendations for management of diabetes during Ramadan: update 2015", BMJ OPEN DIABETES RESEARCH & CARE, cilt.3, sa.1, 2015 | |
dc.identifier.other | av_6fd65914-2813-473c-a672-677c86bb7819 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/77145 | |
dc.identifier.uri | https://doi.org/10.1136/bmjdrc-2015-000108 | |
dc.description.abstract | Since the first ADA working group report on the recommendations for management of diabetes during Ramadan in 2005 and our update in 2010, we received many inquiries asking for regular updates on information regarding education, nutritional habits and new oral and injectable agents that may be useful for the management of patients with diabetes during Ramadan. Patients can be stratified into their risk of hypoglycemia and/or complications prior to the start of the fasting period of Ramadan. Those at high risk of hypoglycemia and with multiple diabetic complications should be advised against prolonged fasting. Even in the lower hypoglycemia risk group, adverse effects may still occur. In order to minimize adverse side effects during fasting in patients with diabetes and improve or maintain glucose control, education and discussion of glucose monitoring and treatment regimens should occur several weeks prior to Ramadan. Agents such as metformin, | |
dc.language.iso | eng | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | ENDOKRİNOLOJİ VE METABOLİZMA | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Endokrinoloji ve Metabolizma Hastalıkları | |
dc.title | Recommendations for management of diabetes during Ramadan: update 2015 | |
dc.type | Makale | |
dc.relation.journal | BMJ OPEN DIABETES RESEARCH & CARE | |
dc.contributor.department | EDC , , | |
dc.identifier.volume | 3 | |
dc.identifier.issue | 1 | |
dc.contributor.firstauthorID | 220555 | |